Reporter brief
Effect of Tirzepatide on Functional Outcomes in Patients With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy: A Multicenter, Randomized, Controlled, Blinded Outcome Assessment Trial
What happened
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract presents only the study protocol and rationale, not completed results, so no efficacy or safety findings can be extracted.
- The mechanism-based rationale (neuroprotection via inflammation and oxidative stress reduction) is theoretical; this study design tests functional outcomes but does not establish mechanisms.
- As a Phase II/proof-of-concept trial, results would not establish tirzepatide as standard care or prove benefit in all stroke populations without larger replication.
Study design and sample
Rct; Human.
Patients with acute ischemic stroke caused by blockage of a large brain artery (large vessel occlusion) who are eligible for and undergoing endovascular thrombectomy
- Design
- Rct
- Sample
- —
- Journal
- yifang zhu
- Published
- Oct 1, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.